Altevogt P - Search Results

1

Lack of CD24 expression in mice reduces the number of leukocytes in the colon.

Bretz NP, Salnikov AV, Doberstein K, Garbi N, Kloess V, Joumaa S, Naumov I, Boon L, Moldenhauer G, Arber N, Altevogt P. Bretz NP, et al. Among authors: altevogt p. Immunol Lett. 2014 Sep;161(1):140-8. doi: 10.1016/j.imlet.2014.06.004. Epub 2014 Jun 20. Immunol Lett. 2014. PMID: 24956310

2

CD24 controls Src/STAT3 activity in human tumors.

Bretz NP, Salnikov AV, Perne C, Keller S, Wang X, Mierke CT, Fogel M, Erbe-Hofmann N, Schlange T, Moldenhauer G, Altevogt P. Bretz NP, et al. Among authors: altevogt p. Cell Mol Life Sci. 2012 Nov;69(22):3863-79. doi: 10.1007/s00018-012-1055-9. Epub 2012 Jul 4. Cell Mol Life Sci. 2012. PMID: 22760497 Free PMC article.

3

CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells.

Schabath H, Runz S, Joumaa S, Altevogt P. Schabath H, et al. Among authors: altevogt p. J Cell Sci. 2006 Jan 15;119(Pt 2):314-25. doi: 10.1242/jcs.02741. Epub 2006 Jan 3. J Cell Sci. 2006. PMID: 16390867

4

CD24 induces localization of beta1 integrin to lipid raft domains.

Runz S, Mierke CT, Joumaa S, Behrens J, Fabry B, Altevogt P. Runz S, et al. Among authors: altevogt p. Biochem Biophys Res Commun. 2008 Jan 4;365(1):35-41. doi: 10.1016/j.bbrc.2007.10.139. Epub 2007 Nov 1. Biochem Biophys Res Commun. 2008. PMID: 17980703

5

CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion.

Bretz N, Noske A, Keller S, Erbe-Hofmann N, Schlange T, Salnikov AV, Moldenhauer G, Kristiansen G, Altevogt P. Bretz N, et al. Among authors: altevogt p. Clin Exp Metastasis. 2012 Jan;29(1):27-38. doi: 10.1007/s10585-011-9426-4. Epub 2011 Oct 8. Clin Exp Metastasis. 2012. PMID: 21984372

6

miR-21-3p is a positive regulator of L1CAM in several human carcinomas.

Doberstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, Müller-Holzner E, Reimer D, Zeimet AG, Altevogt P. Doberstein K, et al. Among authors: altevogt p. Cancer Lett. 2014 Nov 28;354(2):455-66. doi: 10.1016/j.canlet.2014.08.020. Epub 2014 Aug 19. Cancer Lett. 2014. PMID: 25149066

7

Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.

Doberstein K, Harter PN, Haberkorn U, Bretz NP, Arnold B, Carretero R, Moldenhauer G, Mittelbronn M, Altevogt P. Doberstein K, et al. Among authors: altevogt p. Int J Cancer. 2015 Mar 1;136(5):E326-39. doi: 10.1002/ijc.29222. Epub 2014 Sep 25. Int J Cancer. 2015. PMID: 25230579

8

Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas.

Salnikov AV, Bretz NP, Perne C, Hazin J, Keller S, Fogel M, Herr I, Schlange T, Moldenhauer G, Altevogt P. Salnikov AV, et al. Among authors: altevogt p. Br J Cancer. 2013 Apr 16;108(7):1449-59. doi: 10.1038/bjc.2013.102. Epub 2013 Mar 19. Br J Cancer. 2013. PMID: 23511563 Free PMC article.

9

Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation.

Altevogt P, Bretz NP, Ridinger J, Utikal J, Umansky V. Altevogt P, et al. Semin Cancer Biol. 2014 Oct;28:51-7. doi: 10.1016/j.semcancer.2014.04.008. Epub 2014 Apr 24. Semin Cancer Biol. 2014. PMID: 24769223 Review.

10

Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA.

Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N. Sagiv E, et al. Among authors: altevogt p. Cancer Res. 2008 Apr 15;68(8):2803-12. doi: 10.1158/0008-5472.CAN-07-6463. Cancer Res. 2008. PMID: 18413748

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

248 results

Search Page

Filters